Current Status
Not Enrolled
Get Started

Jointly provided by Partners for Advancing Clinical Education (PACE) and Ig National Society, Inc.

Original Release Date: February 2021
Last Review Date: December 2023
Expiration Date: December 2024

Target Audience
This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of immunoglobulin therapy and specialty biologics.

Educational Objectives
Upon completion of this activity, participants should be able to:

Part 1

  • Discuss the components of our immune system.
  • Describe a typical antibody deficiency syndrome that is treated with immunoglobulin.
  • Describe the impact of Ig replacement on the health of patients with PI.

Part 2

  • Define autoinflammatory disorders.
  • Discuss the role of phenotyping and family history in diagnosis.
  • Describe the basics of inflammasome mediated inflammation.
  • Describe the role of cytokine-targeting biologics as therapy for these disorders.

Part 3

  • Review the range of disorders of host defense.
  • Identify the non-infectious co-morbidities associated with PI.
  • Recognize that pediatric and adult PI patients are subject to distinct but overlapping clinical problems.
  • Explain how complexity in a PI patient derives from multiple, interacting problems.

Part 4

  • Explain key aspects of the pathogenesis and clinical presentation of pulmonary disease in primary immunodeficiency.
  • Summarize our understanding of asthma and chronic obstructive pulmonary disease in primary immunodeficiency.
  • Recognize the physiology, clinical presentation, and therapeutic approach to bronchiectasis in primary immunodeficiency.
  • Identify distinct forms of interstitial lung disease occurring in primary immunodeficiency.

Part 5

  • Discuss non-infectious presentations and manifestations of primary immunodeficiency.
  • Formulate a differential diagnosis for children with suspected immunodeficiency.
  • Identify new rare defects of the immune system that cause immunodeficiency.

Part 6

  • Review the nomenclature for monoclonal antibodies.
  • Explain the mechanisms for prolonged hypogammaglobulinemia with biologic therapy.
  • Review the immune and infectious consequences of some of the most frequently used biologics on the immune system.
  • Review the adverse effects of immune check point inhibitors.


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Ig National Society, Inc. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
PACE designates this enduring material for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 4.25 contact hours.

Pharmacy Continuing Education

PACE designates this continuing education activity for 4.25 contact hour(s) (0.425 CEUs) of the Accreditation
Council for Pharmacy Education.
(Universal Activity Number – JA4008073-9999-23-331-H01-P)
Type of Activity: Knowledge

Faculty & Disclosures
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Ken Paris, MD, MPH
Faculty Conflicts of Interest
Consultant/Advisor/Speaker: Takeda; Researcher: Takeda

Lori Broderick, MD, PhD
Faculty Conflicts of Interest
Research Support/Collaboration: IFM Therapeutics, Regeneron, Inc

Richard Wasserman, MD, PhD
Faculty Conflicts of Interest
Consultant/Advisor/Speaker: ADMA Biologicals, CSL Behring, Evolve Biologicals, Kedrion, Korean Green Cross, Grifols, Takeda, Elevare

PJ Magilone, MD, PhD
Faculty Conflicts of Interest
Consultant/Advisor/Speaker: Pharming, Takeda

Jennifer Leiding, MD
Faculty Conflicts of Interest
Speaker/Consultant: CSL Behring, Horizon Pharma, Orchard Therapeutics, and Pharming Research Funding: Horizon Pharma

Mark Ballow, MD
Faculty Conflicts of Interest
Advisory board/Speaker: CSL Behring, Takeda, Grifols DSMB: Ichnos Sciences

This activity was originally supported by an independent educational grant and has been reviewed and relaunched.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit
Participation in this self-study activity should be completed in 4.25 hours. To successfully complete activities and receive CE credit, learners must follow these steps:

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Complete the activity evaluation
  4. Upon completion of all evaluation questions your credit will be made available for download immediately.

Pharmacists: Upon successfully completing the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
For additional information about the accreditation of this activity, please visit